Results of a multicenter phase 1 clinical trial presented today at the 2015 San Antonio Breast Cancer Symposium show that the anti-androgen agent enzalutamide is active and well-tolerated alone and with fulvestrant in patients ...
Dec 7, 2015
0
0
Results from a trial of the anti-cancer drug galeterone show that it is successful in lowering prostate-specific antigen (PSA) levels in men with a form of prostate cancer that is resistant to treatment with hormone therapy ...
Nov 18, 2014
0
0
A University of Houston (UH) scientist and his team are working to develop the next generation of prostate cancer therapies, which are targeted at metabolism.
Feb 28, 2014
0
4
By studying a specific part of the male DNA, it may be possible to refine the interpretation of PSA tests. This would reduce the risk of men being treated for prostate cancer unnecessarily.
Oct 30, 2012
0
0
A small, naturally occurring nucleic acid sequence, called a microRNA, known to regulate a number of different cancers, appears to alter the activity of the androgen receptor, which plays a critical role in prostate cancer. ...
Jul 17, 2012
0
0
An experimental medication safely increases muscle strength and physical functioning among cancer patients with low testosterone levels, a new drug study finds. The results will be presented at The Endocrine Society's 94th ...
Jun 25, 2012
0
0
Patients with castration-resistant prostate cancer had limited side effects and in many cases a drop in prostate-specific antigen expression with galeterone (TOK-001), a small-molecule oral drug, according to phase I data ...
Apr 1, 2012
0
0
The ratio between the second and fourth digits is linked to stretched penile length according to a study published online this week in Asian Journal of Andrology. This finding suggests that digit ratio can predict adult penile ...
Jul 5, 2011
5
0
